Objectives: The role of pelvic lymphadenectomy in patients with lymph node-negative bladder cancer at radical cystectomy (RC) has not yet been examined in detail. We retrospectively reviewed patients who underwent RC with pelvic lymphadenectomy for bladder cancer from January 1987 to March 2008. Methods: We identified consecutive data on 169 patients who underwent RC for bladder cancer. The mean follow-up was 64 months (range: 1 -253 months). Node-positive status (pN(þ)) was seen in 16 patients and 91 were diagnosed as node-negative ( pN (2)). The lymph node status of the remaining 62 patients was unclear (pN(x)). We analysed the association between lymph node status and cancer-specific survival (CSS), and examined the role of the number of retrieved lymph nodes, particularly in pN(2). Results: The median number of retrieved nodes was 12.9 and 10.2 for stage pN(þ) and stage pN(2), respectively. In 91 patients with pN(2), multivariate analysis revealed that pathological T3-4 (P ¼ 0.0276) and less than nine retrieved lymph nodes (P ¼ 0.0108) were independent risk factors for CSS. In a subgroup of 83 patients with pT3-4, Kaplan -Meier curves showed that the 5-year CSS rate in pN(2) patients with less than nine retrieved lymph nodes was 38.8%, which was extremely similar to the 40.8% in pN(þ) and 45.1% in pN(x).
INTRODUCTION
Bladder urothelial carcinoma constitutes nearly 90% of all primary bladder tumours. Approximately 70% of patients with bladder cancer initially present with non-muscle-invasive disease that has not invaded through the lamina propria. However, one-fourth of patients will either present with or subsequently develop muscle-invasive disease (1) . If left untreated, over 85% of patients with muscle-invasive disease will die of the disease within 2 years of diagnosis (2) . Radical cystectomy (RC) is a standard surgical treatment for high-grade, invasive bladder cancer. It is known that pelvic lymph node dissection (PLND) performed at RC provides important pathological information for predicting the prognosis (3 -5) , and bilateral PLND as a part of RC has therapeutic impact to enhance local disease control and also to improve overall survival (6) . Recent studies have indicated that the extent of PLND (7), the retrieved number of lymph nodes (8) and positive lymph node density (9) are important prognostic factors for node-positive (pN(þ)) patients. Meanwhile, there has been a report on the role of PLND in patients with lymph node-negative (pN (2) ) bladder cancer at RC (10) , although its precise role has not yet been examined in detail.
In this study, we retrospectively reviewed patients who underwent RC with PLND for bladder cancer from January 1987 to March 2008. We analysed the association between lymph node status and cancer-specific survival (CSS), and examined the role of the number of retrieved lymph nodes, particularly in pN(2) patients.
PATIENTS AND METHODS
A total of 179 patients underwent RC for refractory non-muscle-invasive or muscle-invasive bladder cancer at our institution between January 1987 and March 2008. One patient who underwent non-curative surgery, three who had tumours of non-urothelial origin and six who had an unclear medical history after RC were excluded. Therefore, we analysed data on 169 consecutive patients who underwent curative cystectomy with or without lymph node dissection for the bladder cancer. The mean follow-up was 64 months (range: 1 -253 months). Of these 169 patients, 127 were men and 42 were women. Median patient age was 68 years (range: 36-87 years).
The preoperative evaluation included ultrasonography, cystoscopy, abdominal and pelvic computed tomography (CT), and chest X-ray. In addition, the patients underwent pelvic magnetic resonance imaging, chest CT and/or bone scan, if clinically indicated. Bladder cancer was histopathologically diagnosed by transurethral resection in all patients before cystectomy. RC was performed with a standard technique, and a regular form of PLND included bilateral internal iliac, external iliac and obturator lymph nodes. Neoadjuvant chemotherapy was administered to 16 patients (10.6%), most of whom had clinical stage T3 or T4 and/or nodal involvement. Postoperatively, 26 patients (15.4%) with stage pT3 or T4 and/or nodal involvement received adjuvant chemotherapy. Patients were followed postoperatively with urinary cytology, and laboratory studies every 3 months for 2 years and every 6 months thereafter. Chest X-rays and CT scans and/or excretory urograms were performed every 6 months until 5 years, and then annually.
Pathologically node-positive status was defined as pN(þ), and node-negative status was pN (2) . The lymph node status in patients who did not undergo PLND or whose number of lymph nodes removed was unknown, was defined as pN(x).
The survival time was analysed from the date of RC. The endpoints of the univariate and multivariate analyses were death from bladder cancer (CSS). Survival estimates were constructed using the Kaplan -Meier method. The log-rank test was used to evaluate the significance of differences. Cox proportional hazard regression analysis was used to assess the prognostic indicators for multivariate analysis. P value of ,0.05 was considered to indicate statistical significance.
RESULTS

CLINICAL CHARACTERISTICS IN TOTAL PATIENT POPULATION
The patient characteristics are summarized in Table 1 . Stage pN(þ) was seen in 16 patients (9.5%) and pN(2) in 91 patients (53.8%). Pathologically, the median number of retrieved nodes was 12.9 and 10.2 for stage pN(þ) and stage pN(2), respectively. The lymph node number of the remaining 62 patients (36.7%) was unclear (pN(x)). The histological type was pure urothelial carcinoma in 132 patients (78.1%) and other histological components with/without urothelial carcinoma in 37 patients (21.9%).
The patients with pN(þ) status had higher pT3-4 stage (93.8%), G3 (93.8%) and LVI (87.5%) than those with another status, respectively. On the other hand, the patients with pNx status had lower G3 (54.8%) and LVI (33.9%) than those with another status, respectively. (2), P ¼ 0.846; Figure 1 ). Next we analysed the prognostic factors in pN(þ) and pN(2) status patients (n ¼ 107; Table 2 ). In univariate analysis, stage T3-4, presence of the G3 component, positive LVI, pN disease and the number of removed lymph nodes (9 vs. ,9 nodes removed) were associated with CSS (all P , 0.05), but advanced age and the presence of carcinoma in situ were not. Multivariate analysis demonstrated that stage T3-4 (P ¼ 0.0016, hazards ratio [HR] 4.84) and less than nine removed lymph nodes (P ¼ 0.0049, HR 3.49) were independently associated with CSS. For the pN(2) status, we summarized the patient characteristics classified by the number of removed lymph nodes at the cut-off value of nine in Table 1 . The 5-year CSS estimate of the group of patients with nine or more lymph nodes dissected was significantly higher than those with less than nine lymph nodes (84.3% vs. 52.7%; P ¼ 0.0006).
SURVIVAL ANALYSIS IN PATIENTS WITH PN(2) STATUS
In a subgroup of 91 patients with node-negative status, stage T3-4, presence of the G3 component and the number of removed lymph nodes (9 vs. ,9 nodes removed) were associated with CSS (all P , 0.05; Table 3 ). Multivariate analysis revealed that pathological stage T3-4 (P ¼ 0.0276, HR 3.26) and less than nine retrieved lymph nodes (P ¼ 0.0108, HR 6.94) were independent risk factors of cancerspecific mortality. Next, we stratified pN(2) patients into three risk groups: a low-risk group (32 patients having no risk factor, risk ratio 1), an intermediate-risk group (33 patients with either of the two risk factors above, risk ratio 3.26 -6.94) and a high-risk group (26 patients with both risk factors, risk ratio 22.62). Kaplan -Meier curves showed that the 5-year CSS rates were 94.7, 77.6 and 38.8%, in the low-, intermediate-and high-risk groups, respectively (P , 0.0001; Figure 2) .
In a subgroup of 83 patients with pT3-4, survival curves were determined according to node status and the risk stratification above (Figure 3) . The 5-year CSS rate for pN (2) patients in the high-risk group was similar to the 40.8% in pN(þ) patients and 45.1% in pN(x) patients in the subgroup of pT3-4 disease. 
DISCUSSION
RC with bilateral PLND is a standard treatment for highgrade, invasive bladder cancer. The main role of PLND has been to accurately diagnose the staging of bladder cancer. If pelvic nodal involvement is proven, it should be recognized as a systemic disease, and then adjuvant chemotherapy might be considered. To provide risk-stratification and the need for adjuvant chemotherapy, various prognostic factors have been identified in patients with lymph node metastases after RC. Recent studies have demonstrated that the prognostic factors such as the total number of lymph nodes removed, the number of positive lymph nodes (8,10 -12) , lymph node density (9,13 -15) and the extent of PLND (16, 17) were important in the patients with positive lymph nodes. However, a few reports have examined patients with negative lymph nodes. Herr et al. also demonstrated that nine or more retrieved lymph nodes improved survival, not only in lymph node-negative patients with stage pT2, but also in those with stage pT3-4, and therefore the number of lymph nodes for predicting survival should be dichotomized as eight or fewer vs. nine or more (10) . In addition, the Southwest Oncology Group study 8710 showed that 10 or more removed lymph nodes contributed to the survival advantage in lymph nodenegative patients (18) . Our results demonstrated that the 5-year CSS estimate of the group of patients in whom nine or more lymph nodes were removed was significantly higher than that of the group with less than nine lymph nodes removed (84.3% vs. 52.7%; P ¼ 0.0006), thereby supporting the findings of the abovementioned studies (10, 18) . Next, we classified the patients in pN(2) status according to their pT stage and the number of removed lymph nodes, which was independently associated with CSS in multivariate analysis, in order to detect the poor prognostic subgroup or 'true' lymph node-negative status in pN(2) status. In our study, the most interesting finding is that the 5-year CSS rate in N(2) patients in the high-risk group ( pT3-4 N(2) with less than nine retrieved lymph nodes) was 38.8%, which was similar to the 40.8% in pT3-4 N(þ) patients and 45.1% in pT3-4 N(x) patients ( Figure 3 ). Our data demonstrated that the pN(2) patients with pT3-4 status and less than nine removed lymph nodes or an unclear number of nodes may still have micrometastasis remaining owing to no or ineffective removal of lymph nodes and/or imprecise examination.
Resection of an adequate number of lymph nodes is more likely to remove positive lymph nodes and precisely identify lymph node-negative disease, whereas a poor operation including only a few negative lymph nodes (for example; less than nine retrieved lymph nodes in our study) may leave positive lymph nodes behind. It is absolutely vital for an accurate diagnosis of the pathological stage that surgeons completely perform a wide resection around the bladder and pelvic lymph nodes, and that pathologists carefully examine the specimens, even in clinically node-negative patients. Furthermore, sufficient PLND has the possibility to destroy the lymph node networks that contribute to subsequent metastasis. Resection of more lymph nodes may play a role in preventing late lymphangiogenic metastasis and improving the prognosis for lymph node-negative patients. Our data imply that at least nine lymph nodes retrieved may be reasonable as a minimum number that can be easily achieved by most urologists and evaluated by most pathologists using routine methods to detect 'true' lymph node-negative disease.
CONCLUSIONS
The present findings suggest that pT3-4 and dissection of less than nine lymph nodes were independent risk factors for the cases of invasive bladder cancer that were lymph node- Figure 2 . CSS of patients with negative lymph node status (not including pNx status) stratified by independent risk factors ( pathological stage and number of removed nodes). The three risk groups included a low-risk group (32 patients having no risk factor, risk ratio 1), an intermediate-risk group (33 patients with either of the two risk factors above, risk ratio 3.26 -6.94) and a high-risk group (26 patients with both risk factors, risk ratio 22.62) (P , 0.0001). Figure 3 . CSS of pN(þ), pN(2) according to the risk-stratification, and pN(x) patients with pT3-4 disease. The risk-stratification includes three groups: a low-risk group (32 patients having no risk factor, risk ratio 1), an intermediate-risk group (33 patients with either of the two risk factors above, risk ratio 3.26 -6.94) and a high-risk group (26 patients with both risk factors, risk ratio 22.62). The 5-year CSS rate in the high-risk group was 38.3%, which was similar to the 40.8% in pN(þ) patients and 45.1% in pN(x) patients.
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Lymphadenectomy in node-negative bladder cancer negative and that these risk factors were statistically associated with the CSS. Furthermore, the 5-year CSS in node-negative patients in the high-risk group stratified by these risk factors was similar to that in pT3-4 N(þ) status and pT3-4 N(x). We believe that at least nine lymph nodes should be removed to improve survival in pN(2) patients at RC, and that lymphadenectomy would provide not only information on the prognosis, but also on the therapeutic impact of treating pT3-4 invasive bladder cancer.
